WO1999033481A2 - Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia - Google Patents
Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia Download PDFInfo
- Publication number
- WO1999033481A2 WO1999033481A2 PCT/EP1998/008532 EP9808532W WO9933481A2 WO 1999033481 A2 WO1999033481 A2 WO 1999033481A2 EP 9808532 W EP9808532 W EP 9808532W WO 9933481 A2 WO9933481 A2 WO 9933481A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igf
- treatment
- useful
- compositions
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU24182/99A AU2418299A (en) | 1997-12-26 | 1998-12-22 | Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
EP98966697A EP1039924A2 (en) | 1997-12-26 | 1998-12-22 | Process using the growth factor igf-1 in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9702702 | 1997-12-26 | ||
ES9702702A ES2146530B1 (en) | 1997-12-26 | 1997-12-26 | USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999033481A2 true WO1999033481A2 (en) | 1999-07-08 |
WO1999033481A3 WO1999033481A3 (en) | 1999-09-10 |
Family
ID=8301638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/008532 WO1999033481A2 (en) | 1997-12-26 | 1998-12-22 | Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1039924A2 (en) |
AR (1) | AR014196A1 (en) |
AU (1) | AU2418299A (en) |
ES (1) | ES2146530B1 (en) |
WO (1) | WO1999033481A2 (en) |
ZA (1) | ZA9811896B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1109572A2 (en) * | 1998-09-03 | 2001-06-27 | Neuronz Limited | Neuroprotection |
WO2003077940A1 (en) * | 2002-02-28 | 2003-09-25 | Consejo Superior De Investigaciones Científicas | Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5492891A (en) * | 1991-09-05 | 1996-02-20 | Novo Nordisk A/S | Method for treatment of patients with chronic liver disease |
US5633228A (en) * | 1992-06-12 | 1997-05-27 | Cephalon, Inc., | Prevention and treatment of peripheral neuropathy |
-
1997
- 1997-12-26 ES ES9702702A patent/ES2146530B1/en not_active Expired - Fee Related
-
1998
- 1998-12-22 EP EP98966697A patent/EP1039924A2/en not_active Withdrawn
- 1998-12-22 AU AU24182/99A patent/AU2418299A/en not_active Abandoned
- 1998-12-22 WO PCT/EP1998/008532 patent/WO1999033481A2/en not_active Application Discontinuation
- 1998-12-28 AR ARP980106700 patent/AR014196A1/en unknown
- 1998-12-28 ZA ZA9811896A patent/ZA9811896B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5492891A (en) * | 1991-09-05 | 1996-02-20 | Novo Nordisk A/S | Method for treatment of patients with chronic liver disease |
US5633228A (en) * | 1992-06-12 | 1997-05-27 | Cephalon, Inc., | Prevention and treatment of peripheral neuropathy |
Non-Patent Citations (2)
Title |
---|
FERNANDEZ A M ET AL: "Insulin-like growth factor I restores motor coordination in a rat model o cerebellar ataxia." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 FEB 3) 95 (3) 1253-8, XP002102483 * |
FERNANDEZ, A. M. ET AL: "Insulin - like growth factor modulates functional recovery in a rat model of cerebellar ataxia." MEETING INFO.: 27TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE NEW ORLEANS, LOUISIANA, USA OCTOBER 25-30, 1997, -& SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, page 1451 XP002102591 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1109572A2 (en) * | 1998-09-03 | 2001-06-27 | Neuronz Limited | Neuroprotection |
EP1109572A4 (en) * | 1998-09-03 | 2004-11-24 | Neuronz Ltd | Neuroprotection |
US7304029B1 (en) | 1998-09-03 | 2007-12-04 | Neuren Pharmaceuticals Ltd. | Neuroprotective effect of growth hormone |
WO2003077940A1 (en) * | 2002-02-28 | 2003-09-25 | Consejo Superior De Investigaciones Científicas | Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases |
ES2207387A1 (en) * | 2002-02-28 | 2004-05-16 | Consejo Sup. Investig. Cientificas | Chemical igf-i composition for the treatment and prevention of neurodegenerative diseases |
Also Published As
Publication number | Publication date |
---|---|
EP1039924A2 (en) | 2000-10-04 |
AU2418299A (en) | 1999-07-19 |
AR014196A1 (en) | 2001-02-07 |
ZA9811896B (en) | 1999-06-28 |
ES2146530B1 (en) | 2001-04-16 |
WO1999033481A3 (en) | 1999-09-10 |
ES2146530A1 (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aloisi et al. | ‘Mirror pain’in the formalin test: behavioral and 2-deoxyglucose studies | |
Li et al. | Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse | |
DE69831971T2 (en) | SUPPRESSION OF CHANGES ASSOCIATED WITH BETA AMYLOID AT ALZHEIMER | |
EP0659083B1 (en) | Prevention and treatment of peripheral neuropathy | |
DE69821872T2 (en) | Teriparatid-containing stabilized solutions | |
Nyakas et al. | Beneficial effect of chronic treatment with Org 2766 and α-MSH on impaired reversal learning of rats with bilateral lesions of the parafascicular area | |
Vergani et al. | Systemic administration of insulin‐like growth factor decreases motor neuron cell death and promotes muscle reinnervation | |
Kanje et al. | Effects of growth hormone treatment on the regeneration of rat sciatic nerve | |
Jakobsen et al. | Early and dose‐dependent decrease of retrograde axonal transport in acrylamide‐intoxicated rats | |
DE60012517T2 (en) | METHODS OF TREATING DIABETES | |
JPH09509140A (en) | How to treat neurological disorders | |
Rende et al. | Modulation of low‐affinity nerve growth factor receptor in injured adult rat spinal cord motoneurons | |
WO1999033481A2 (en) | Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia | |
Tomas et al. | Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects | |
DE60028559T2 (en) | TREATMENT OF MULTIPLERSCLEROSIS WITH A COMBINATION OF INTERFERON AND GROWTH HORMONE | |
Br et al. | The retrograde fast component of axonal transport in motor and sensory nerves of the rat during administration of 2, 5-hexanedione | |
DE3239710C2 (en) | Peptide with nerve-regenerating properties | |
US6440928B1 (en) | Method for treating diabetic neuropathy with NGF | |
CN114177186A (en) | Application of trehalose in neuroprotective drugs | |
US5830857A (en) | Method of treating epilepsy | |
Jordan | Morphological effects of ciliary neurotrophic factor treatment during neuromuscular synapse elimination | |
DE60315330T2 (en) | BICISTRONIC VECTOR ONE VEGF AND ONE FGF ENCODED, USE THEREOF | |
DE60120371T2 (en) | USING GROWTH HORMONE IN LESS BOXES | |
Skottner et al. | Effects of human growth hormone on peripheral nerve regeneration | |
EP0916345B1 (en) | Human growth hormone for treating anorexia nervosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998966697 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998966697 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase in: |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998966697 Country of ref document: EP |